Is Infinium Pharma overvalued or undervalued?

As of 17 November 2025, Infinium Pharma's valuation grade has moved from very expensive to attractive, indicating a significant shift in its perceived value. The company is currently assessed as undervalued, especially when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE ratio of 44.28, an EV to EBITDA of 23.90, and a ROE of 7.68%.
In terms of peer comparison, Infinium Pharma's PE ratio is notably higher than Sun Pharma's 36.69 and significantly lower than Divi's Lab's 69.78, which reflects a more favorable valuation position. Additionally, while Infinium's PEG ratio stands at 0.00, indicating potential for growth, peers like Cipla and Dr. Reddy's Labs have PEG ratios of 1.28 and 2.22, respectively, suggesting that Infinium may offer better value relative to its growth prospects. The recent performance of Infinium Pharma, with a year-to-date return of -19.74% compared to the Sensex's 10.02%, further reinforces the notion that the stock is undervalued in the current market environment.